Current Report Filing (8-k)
September 08 2022 - 5:01PM
Edgar (US Regulatory)
0001270073
false
0001270073
2022-09-08
2022-09-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): September 8, 2022
Intercept
Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware | |
001-35668 | |
22-3868459 |
(State or other jurisdiction | |
(Commission | |
(IRS Employer |
of incorporation) | |
File Number) | |
Identification No.) |
305 Madison Avenue, Morristown, NJ 07960
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including
area code: (646) 747-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading
Symbol(s) |
Name of each exchange on which
registered |
Common Stock, par value $0.001 per share |
ICPT |
Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 3.02 Unregistered Sales of Equity
Securities.
On September 8, 2022, Intercept Pharmaceuticals, Inc. (the “Company”)
closed its previously announced exchange of existing convertible senior secured notes due 2026 with an existing noteholder.
This noteholder is an institutional “accredited investor”
(within the meaning of Rule 501(a)(1), (2), (3) or (7) promulgated under the Securities Act of 1933, as amended (the “Securities
Act”)) and/or a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act).
The Company exchanged $9.3 million principal amount of existing notes
for approximately $5.2 million in cash and 318,000 shares of newly issued common stock, par value $0.001 per share (equivalent to $5.2
million at the Company’s closing stock price of $16.32 on September 6, 2022), for total consideration of $10.4 million.
The common stock was issued in a private placement in reliance on the
exemption from registration provided by Section 4(a)(2) of the Securities Act. The Company relied on this exemption from registration
based in part on representations made by the noteholder in its exchange agreement.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INTERCEPT PHARMACEUTICALS, INC. |
|
|
|
By: |
/s/ Andrew Saik |
|
Name: |
Andrew Saik |
|
Title: |
Chief Financial Officer |
Date: September 8, 2022
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Sep 2023 to Sep 2024